Study Summary
This trial will test a new drug to treat two types of brain inflammation: NMDAR and LGI1 encephalitis.
- LGI1 Autoimmune Encephalitis
- NMDA Receptor Autoimmune Encephalitis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: From Week 52 up to 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
4 Treatment Groups
LGI1 AIE cohort
1 of 4
NMDAR autoimmune encephalitis (AIE) cohort
1 of 4
NMDAR autoimmune encephalitis (AIE) Placebo cohort
1 of 4
LGI1 AIE Placebo cohort
1 of 4
Experimental Treatment
Non-Treatment Group
152 Total Participants · 4 Treatment Groups
Primary Treatment: LGI1 AIE cohort · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How does the LGI1 AIE cohort impact patient safety?
"The LGI1 AIE cohort has ample evidence of its efficacy, and multiple studies have demonstrated its safety; therefore, we rate it a 3 on the risk spectrum." - Anonymous Online Contributor
Are there any vacant vacancies available in this medical trial?
"Affirmative, clinicaltrials.gov is hosting the details of this research which initially went public on September 27th 2022 and had its most recent update on November 8th 2022. 152 patients need to be registered at a single medical facility." - Anonymous Online Contributor
How many participants have been admitted to this clinical trial thus far?
"Affirmative. According to clinicaltrials.gov, this research trial is actively recruiting and was initially posted on September 27th 2022; the posting has been recently revised as of November 8th 2022. The study requires 152 participants from 1 medical centre." - Anonymous Online Contributor